Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach

Utility of 111Indium-pentetreotide Scintigraphy in Patients with Neuroendocrine Tumors

(2012) Narek Shaverdian et al.   ANNALS OF SURGICAL ONCOLOGY

Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice

(2012) Edmond Rust et al.   CANCER IMAGING

Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors

(2011) Kiran K. Turaga et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Current knowledge on diagnosis and staging of neuroendocrine tumors

(2011) Kjell Öberg et al.   CANCER AND METASTASIS REVIEWS

18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors

(2010) T. Binderup et al.   CLINICAL CANCER RESEARCH

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET

(2010) T. Binderup et al.   JOURNAL OF NUCLEAR MEDICINE

The Pathologic Classification of Neuroendocrine Tumors

(2010) David S. Klimstra et al.   PANCREAS

Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors

(2009) E. Garin et al.   JOURNAL OF NUCLEAR MEDICINE

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

(2009) Dik J. Kwekkeboom et al.   NEUROENDOCRINOLOGY

Functional imaging of neuroendocrine tumors with combined PET/CT using68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and18F-FDG

(2008) Irfan Kayani et al.   CANCER

Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors

(2008) Amani Asnacios et al.   JOURNAL OF CLINICAL ONCOLOGY

Gastroenteropancreatic neuroendocrine tumours

(2008) Irvin M Modlin et al.   LANCET ONCOLOGY